Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| TT Ten63 TherapeuticsCompany profile Develops AI-driven drug discovery platform for first- and best-in-class therapeutics Develops AI-driven drug discovery platform for first- and best-in-class therapeutics | $45M | StrategicUndisclosed | Biotech, AI | United States | Investors | |
 Altesa BioSciencesCompany profile Clinical-stage developer of oral antiviral medicines for people with chronic lung disease. Clinical-stage developer of oral antiviral medicines for people with chronic lung disease. | $75M | Series B | Biotech | United States | Investors | |
| L LanzaJetCompany profile Develops technology for producing Sustainable Aviation Fuel (SAF) and other alternative fuels Develops technology for producing Sustainable Aviation Fuel (SAF) and other alternative fuels | $47M | Growth | Biotech, Climate tech | United States | Investors | |
| LT Lario TherapeuticsCompany profile Develops precision medicines for epileptic and neurological disorders Develops precision medicines for epileptic and neurological disorders | $2.4M | GrantUndisclosed | Biotech | United Kingdom | Investors | |
| F FlinnCompany profile Develops AI-based software to automate regulatory and quality processes in medtech and pharma Develops AI-based software to automate regulatory and quality processes in medtech and pharma | $20M | Series A | Biotech, Healthtech | Austria | Investors | |
| KB Develops therapies for neurodegenerative diseases. | $175M | Series A | Biotech | United States | Investors | |
| SP Develops next-generation peptide radioligand therapies for cancer | $18M | Series A | Biotech | United States | Investors | |
| P Pharmacelera uses quantum-mechanics methods and AI in drug discovery. | €6M | Growth | Biotech | Spain | Investors | |
| SB Sift BiosciencesCompany profile Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases | $3.7M | Pre-SeedPre-seed | Biotech | United States | Investors | |
| BT Develops precision immune therapies for glioblastoma | €2.5M | StrategicUndisclosed | Biotech | Sweden | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.